UBS Group
TBIO

UBS Group’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

UBS Group’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,386
Closed -$314K – 10680
2021
Q2 		$314K Sell
11,386
-86,174
-88% -$1.69M ﹤0.01% 5057
2021
Q1 		$1.61M Buy
97,560
+94,145
+2,757% +$2.14M ﹤0.01% 3786
2020
Q4 		$63K Sell
3,415
-28,890
-89% -$517K ﹤0.01% 5990
2020
Q3 		$440K Buy
32,305
+27
+0.1% +$416 ﹤0.01% 4295
2020
Q2 		$578K Buy
32,278
+9,903
+44% +$149K ﹤0.01% 4018
2020
Q1 		$223K Sell
22,375
-27,042
-55% -$222K ﹤0.01% 4637
2019
Q4 		$402K Buy
49,417
+34,468
+231% +$318K ﹤0.01% 5035
2019
Q3 		$148K Buy
14,949
+14,104
+1,669% +$133K ﹤0.01% 5491
2019
Q2 		$11K Buy
+845
New +$8.91K ﹤0.01% 7041
2018
Q4 		– Sell
-2,370
Closed -$24K – 8456
2018
Q3 		$24K Buy
+2,370
New +$27.6K ﹤0.01% 6710

UBS Group's TBIO Position: Q3 2021 in Review

UBS Group sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 11,386 shares — an estimated $314K sold.

UBS Group first reported a position in TBIO in Q3 2018 and held it in 10 quarters. The position peaked at $1.61M in Q1 2021. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.

  • UBS Group reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • UBS Group sold 11,386 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $314K.
  • UBS Group first reported a position in Translate Bio, Inc. Common Stock in Q3 2018 and held it in 10 quarters.
  • UBS Group's Translate Bio, Inc. Common Stock position peaked at $1.61M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.

Based on UBS Group's 13F filing for Q3 2021, filed 15 Nov 2021.